All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What are the benefits of adding anti-CD20 therapy to treatment with targeted agents in CLL?

During the Lymphoma, Leukemia & Myeloma 2021 Virtual Congress, the Lymphoma Hub was pleased to speak to Bruce Cheson, Georgetown University Hospital, Washington DC, US. We asked, What are the benefits of adding anti-CD20 therapy to treatment with targeted agents in chronic lymphocytic leukemia (CLL)?

What are the benefits of adding anti-CD20 therapy to treatment with targeted agents in CLL?

Cheson begins by highlighting two trials that failed to show an advantage when adding rituximab to ibrutinib and current second generation anti-CD20s e.g. Obinutuzumab, which are shown to have some advantages over rituximab. Finally, he discusses the GENUINE trial where ublituximab was found to be superior to ibrutinib.

 

Share: